Item 8.01 Other Events.

On July 13, 2020, Equillium, Inc. (the "Company") announced that a clinical trial conducted by its partner, Biocon Limited, demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19 in India and that the Drugs Controller General of India, the regulatory agency that oversees drug approvals in India, has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome in India. The Company, which has the right to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand, is planning to conduct a global randomized, controlled clinical trial of itolizumab in COVID-19 patients for which it will file a U.S. investigational new drug application. A copy of the press release discussing these matters is filed as Exhibit 99.01, and incorporated by reference in, this report.

Item 9.01 Financial Statements and Exhibits.





 (d)   Exhibit
       Number                               Description.

       99.01       Press release, dated July 13, 2020, issued by Equillium, Inc.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses